TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sanuwave Health ( (SNWV) ) has provided an announcement.
On September 25, 2025, Sanuwave Health appointed Daniel Coyle as the new Chief Operating Officer, succeeding Peter Stegagno, who transitioned to Chief Regulatory Officer. Additionally, the company announced the termination of President Andrew Walko, effective October 24, 2025, with no immediate plans to appoint a successor.
The most recent analyst rating on (SNWV) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
Spark’s Take on SNWV Stock
According to Spark, TipRanks’ AI Analyst, SNWV is a Neutral.
Sanuwave Health’s overall stock score is primarily impacted by weak financial performance and valuation concerns. Despite strong revenue growth and improved EBITDA, significant risks remain due to negative equity and cash flow issues. Technical analysis suggests potential volatility, and the lack of a dividend yield further limits appeal.
To see Spark’s full report on SNWV stock, click here.
More about Sanuwave Health
Sanuwave Health, Inc. operates in the medical device industry, focusing on developing and commercializing non-invasive, biological response-activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Average Trading Volume: 52,110
Technical Sentiment Signal: Buy
Current Market Cap: $296.5M
For a thorough assessment of SNWV stock, go to TipRanks’ Stock Analysis page.